Grant Waterer Mbbs

List of Publications by Citations

174 papers	8,647 citations	36 h-index	90 g-index
220 ext. papers	11,023 ext. citations	5.4 avg, IF	6.16 L-index

#	Paper	IF	Citations
174	Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clinical Infectious Diseases*, **2016**, 63, e61-e111	11.6	1499
173	Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *New England Journal of Medicine*, **2015**, 373, 415-27	59.2	1187
172	Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, e45-e67	10.2	1106
171	SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. *Clinical Infectious Diseases*, **2008**, 47, 375-84	11.6	351
170	Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clinical Infectious Diseases*, **2016**, 63, 575-82	11.6	232
169	Clinical practice. Community-acquired pneumonia. *New England Journal of Medicine*, **2014**, 370, 543-51	59.2	169
168	Severity of pneumococcal pneumonia associated with genomic bacterial load. *Chest*, **2009**, 136, 832-840	5.3	163
167	The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. *Clinical Infectious Diseases*, **2008**, 46, 1513-21	11.6	162
166	Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. *Chest*, **2003**, 124, 2229-38	5.3	145
165	Association between surfactant protein B + 1580 polymorphism and the risk of respiratory failure in adults with community-acquired pneumonia. *Critical Care Medicine*, **2004**, 32, 1115-9	1.4	116
164	Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia. *Clinical Infectious Diseases*, **2017**, 65, 183-190	11.6	112
163	Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. *Chest*, **2012**, 142, 394-400	5.3	112
162	Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. *Chest*, **2006**, 130, 11-5	5.3	112
161	The impact of estrogen and progesterone on asthma. *Annals of Allergy, Asthma and Immunology*, **2003**, 90, 284-91; quiz 291-3, 347	3.2	111
160	Legionella and community-acquired pneumonia: a review of current diagnostic tests from a clinicianℝ viewpoint. *American Journal of Medicine*, **2001**, 110, 41-8	2.4	100
159	Analysis of National Trends in Admissions for Pulmonary Embolism. *Chest*, **2016**, 150, 35-45	5.3	99
158	Medium-term survival after hospitalization with community-acquired pneumonia. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 169, 910-4	10.2	95

157	Advances in the causes and management of community acquired pneumonia in adults. *BMJ, The*, **2017**, 358, j2471	5.9	91
156	Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. *Clinical Infectious Diseases*, **2016**, 63, 300-9	11.6	89
155	Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. *Critical Care Medicine*, **2003**, 31, 1367-72	1.4	79
154	Incidence of cardiovascular events after hospital admission for pneumonia. *American Journal of Medicine*, **2011**, 124, 244-51	2.4	71
153	Alleles carried at positions -819 and -592 of the IL10 promoter affect transcription following stimulation of peripheral blood cells with Streptococcus pneumoniae. *Immunogenetics*, **2003**, 55, 629-32	3.2	71
152	Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 609-620	10.2	70
151	Management of community-acquired pneumonia in adults. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 157-64	10.2	69
150	Increasing threat of Gram-negative bacteria. *Critical Care Medicine*, **2001**, 29, N75-81	1.4	69
149	The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. *Chest*, **1999**, 116, 1278-81	3.3	64
148	A quantitative LightCycler PCR to detect Streptococcus pneumoniae in blood and CSF. *Diagnostic Microbiology and Infectious Disease*, **2003**, 47, 407-14	2.9	56
147	Pleural infection: changing bacteriology and its implications. *Respirology*, **2011**, 16, 598-603	3.6	49
146	Community-Acquired Pneumonia Visualized on CT Scans but Not Chest Radiographs: Pathogens, Severity, and Clinical Outcomes. *Chest*, **2018**, 153, 601-610	5.3	48
145	Influenza A/H1N1_09: Australia and New Zealand's winter of discontent. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 300-6	10.2	45
144	Five-year outcome in COPD patients after their first episode of acute exacerbation treated with non-invasive ventilation. *Respirology*, **2010**, 15, 1084-91	3.6	43
143	Periodontitis and airway obstruction. *Journal of Periodontology*, **2005**, 76, 2161-7	4.6	43
142	Predictors of in-hospital vs postdischarge mortality in pneumonia. *Chest*, **2012**, 142, 476-481	5.3	41
141	Use of non-pharmaceutical interventions to reduce the transmission of influenza in adults: A systematic review. *Respirology*, **2015**, 20, 896-903	3.6	38
140	The septic shock associated HSPA1B1267 polymorphism influences production of HSPA1A and HSPA1B. *Intensive Care Medicine*, **2004**, 30, 1761-7	14.5	37

139	Airflow limitation is underrecognized in well-functioning older people. *Journal of the American Geriatrics Society*, **2001**, 49, 1032-8	5.6	36
138	Influenza vaccine effectiveness against hospitalisation with confirmed influenza in the 2010-11 seasons: a test-negative observational study. *PLoS ONE*, **2013**, 8, e68760	3.7	34
137	Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. *Chest*, **2010**, 137, 805-11	5.3	34
136	Susceptibility to pulmonary disease due to Mycobacterium avium-intracellulare complex may reflect low IL-17 and high IL-10 responses rather than Th1 deficiency. *Clinical Immunology*, **2010**, 137, 296-302	9	34
135	Endotoxin induced TNF and IL-10 mRNA production is higher in male than female donors: correlation with elevated expression of TLR4. *Cellular Immunology*, **2008**, 251, 69-71	4.4	34
134	Repeated Vaccination Does Not Appear to Impact Upon Influenza Vaccine Effectiveness Against Hospitalization With Confirmed Influenza. *Clinical Infectious Diseases*, **2017**, 64, 1564-1572	11.6	33
133	Discriminant validity of the Hospital Anxiety and Depression Scale, Beck Depression Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of depression and anxiety in patients with chronic obstructive pulmonary disease. *Chronic Respiratory Disease*, **2016**, 13, 220-8	3	33
132	Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration. *Clinical Infectious Diseases*, **2019**, 68, 940-948	11.6	33
131	Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. *Chest*, **2009**, 135, 165-172	5.3	32
130	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. *Cytokine*, **2016**, 88, 267-273	4	31
129	FluCAN 2009: initial results from sentinel surveillance for adult influenza and pneumonia in eight Australian hospitals. *Medical Journal of Australia*, **2011**, 194, 169-74	4	29
128	Science review: Genetic variability in the systemic inflammatory response. *Critical Care*, **2003**, 7, 308-14	10.8	29
127	Reducing electrostatic charge on spacer devices and bronchodilator response. *British Journal of Clinical Pharmacology*, **2000**, 50, 277-80	3.8	29
126	Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis. *MSphere*, **2018**, 3,	5	28
125	Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review. *Therapeutic Advances in Respiratory Disease*, **2016**, 10, 235-55	4.9	28
124	Feasibility of real-time polymerase chain reaction in whole blood to identify Streptococcus pneumoniae in patients with community-acquired pneumonia. *Diagnostic Microbiology and Infectious Disease*, **2008**, 61, 72-5	2.9	28
123	Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia. *Current Opinion in Infectious Diseases*, **2005**, 18, 157-63	5.4	28
122	Genetic susceptibility to pneumonia. *Clinics in Chest Medicine*, **2005**, 26, 29-38	5.3	27

121	Trends in pathogens among patients hospitalized for pneumonia from 1993 to 2011. *JAMA Internal Medicine*, **2014**, 174, 1837-9	11.5	26
120	Pneumonia: an arrhythmogenic disease?. *American Journal of Medicine*, **2013**, 126, 43-8	2.4	26
119	Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia. *Chest*, **2016**, 150, 819-828	5.3	26
118	Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. *International Journal of COPD*, **2012**, 7, 271-82	3	25
117	Bioterrorism for the respiratory physician. *Respirology*, **2009**, 14, 5-11	3.6	25
116	Genetics of sepsis and pneumonia. *Current Opinion in Critical Care*, **2003**, 9, 384-9	3.5	25
115	Antibiotic Stewardship in the Intensive Care Unit. An Official American Thoracic Society Workshop Report in Collaboration with the AACN, CHEST, CDC, and SCCM. *Annals of the American Thoracic Society*, **2020**, 17, 531-540	4.7	24
114	Genetic predisposition to respiratory infection and sepsis. *Critical Reviews in Clinical Laboratory Sciences*, **2011**, 48, 250-68	9.4	24
113	Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. *New England Journal of Medicine*, **2020**, 383, 1635-1644	59.2	24
112	Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia. *Respirology*, **2015**, 20, 660-6	3.6	23
111	We should be measuring genomic bacterial load and virulence factors. *Critical Care Medicine*, **2010**, 38, S656-62	1.4	22
110	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. *Chest*, **2020**, 158, 1896-1911	5.3	20
109	Pulmonary capillaritis associated with the antiphospholipid antibody syndrome and rapid response to plasmapheresis. *Respirology*, **1999**, 4, 405-8	3.6	20
108	Airway defense mechanisms. *Clinics in Chest Medicine*, **2012**, 33, 199-209	5.3	19
107	Intracellular adhesion molecule Gly241Arg polymorphism has no impact on ARDS or septic shock in community-acquired pneumonia. *Chest*, **2002**, 121, 85S-86S	5.3	19
106	In-Hospital Deaths Among Adults With Community-Acquired Pneumonia. *Chest*, **2018**, 154, 628-635	5.3	18
105	Why should we measure bacterial load when treating community-acquired pneumonia?. *Current Opinion in Infectious Diseases*, **2011**, 24, 137-41	5.4	18
104	Choosing the right combination therapy in severe community-acquired pneumonia. *Critical Care*, **2006**, 10, 115	10.8	17

103	Healthcare-associated pneumonia: a US disease or relevant to the Asia Pacific, too?. *Respirology*, **2013**, 18, 923-32	3.6	16
102	Public health management of pandemic (H1N1) 2009 infection in Australia: a failure!. *Respirology*, **2010**, 15, 51-6	3.6	16
101	Pneumococcal and Legionella Urinary Antigen Tests in Community-acquired Pneumonia: Prospective Evaluation of Indications for Testing. *Clinical Infectious Diseases*, **2019**, 68, 2026-2033	11.6	16
100	Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia. *Chest*, **2014**, 145, 1114-1120	5.3	15
99	Migraine precipitated by adenosine. *Medical Journal of Australia*, **1995**, 162, 389, 391	4	15
98	Levels of anti-cytokine antibodies may be elevated in patients with pulmonary disease associated with non-tuberculous mycobacteria. *Cytokine*, **2014**, 66, 160-3	4	14
97	A case of pulmonary hemorrhage due to drug-induced pneumonitis secondary to ticagrelor therapy. *Chest*, **2014**, 145, 639-641	5.3	14
96	Determinants for concomitant anxiety and depression in people living with chronic obstructive pulmonary disease. *Journal of Psychosomatic Research*, **2019**, 120, 60-65	4.1	13
95	Decreasing beta-lactam resistance in Pneumococci from the Memphis region: analysis of 2,152 isolates From 1996 to 2001. *Chest*, **2003**, 124, 519-25	5.3	12
94	Genetics of community-acquired pneumonia. *Seminars in Respiratory and Critical Care Medicine*, **2005**, 26, 553-62	3.9	12
93	Bacteremic community-acquired pneumonia in an immunocompetent adult due to Burkholderia cepacia. *Chest*, **1999**, 116, 1842-3	5.3	12
92	Community-acquired Pneumonia: A Global Perspective. *Seminars in Respiratory and Critical Care Medicine*, **2016**, 37, 799-805	3.9	12
91	Bacteriology and clinical outcomes of patients with culture-positive pleural infection in Western Australia: A 6-year analysis. *Respirology*, **2019**, 24, 171-178	3.6	12
90	Update in adult community-acquired pneumonia: key points from the new American Thoracic Society/Infectious Diseases Society of America 2019 guideline. *Current Opinion in Pulmonary Medicine*, **2020**, 26, 203-207	3	11
89	Respiratory infections: a current and future threat. *Respirology*, **2009**, 14, 651-5	3.6	11
88	Combination antibiotic therapy with macrolides in community-acquired pneumonia: more smoke but is there any fire?. *Chest*, **2003**, 123, 1328-9	5.3	11
87	Human pleural fluid is a potent growth medium for Streptococcus pneumoniae. *PLoS ONE*, **2017**, 12, e0188833	3.7	11
86	Severity Scores and Community-acquired Pneumonia. Time to Move Forward. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1236-1238	10.2	10

85	Quantitative rt-PCR holds promise as a screening tool for patients with severe sepsis. *EMA - Emergency Medicine Australasia*, **2011**, 23, 502-6	1.5	10
84	Genetic variation in MYLK and lung injury in children and adults with community-acquired pneumonia. *Pediatric Critical Care Medicine*, **2010**, 11, 731-6	3	10
83	Anemia in hospitalized patients: an overlooked risk in medical care. *Transfusion*, **2018**, 58, 2522-2528	2.9	10
82	Rapid diagnostic tests for defining the cause of community-acquired pneumonia. *Current Opinion in Infectious Diseases*, **2015**, 28, 185-92	5.4	9
81	Improving outcomes from community-acquired pneumonia. *Current Opinion in Pulmonary Medicine*, **2015**, 21, 219-25	3	9
80	Searching for an immunogenetic factor that will illuminate susceptibility to non-tuberculous mycobacterial disease. *Human Immunology*, **2013**, 74, 1382-5	2.3	9
79	Beta2 adrenergic receptor (ADR2) haplotype pair (2/4) is associated with severe asthma. *PLoS ONE*, **2014**, 9, e93695	3.7	9
78	High-mobility group box 1 (HMGB1) as a potential therapeutic target in sepsis--more questions than answers. *Critical Care Medicine*, **2007**, 35, 1205-6	1.4	9
77	Appropriate microbiological testing in community-acquired pneumonia. *Chest*, **2001**, 119, 5-7	5.3	9
76	Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2012: the Influenza Complications Alert Network (FluCAN). *Communicable Diseases Intelligence*, **2013**, 37, E246-52		9
75	Diagnosing Viral and Atypical Pathogens in the Setting of Community-Acquired Pneumonia. *Clinics in Chest Medicine*, **2017**, 38, 21-28	5.3	8
74	Hot topics and current controversies in community-acquired pneumonia. *Breathe*, **2019**, 15, 216-225	1.8	8
73	Inhaled corticosteroids and the increased risk of pneumonia. *Therapeutic Advances in Respiratory Disease*, **2013**, 7, 225-34	4.9	8
72	Immunological Markers of Lung Disease Due to Non-Tuberculous Mycobacteria. *Disease Markers*, **2010**, 29, 103-109	3.2	8
71	Can immunogenetics illuminate the diverse manifestations of respiratory infections?. *Therapeutic Advances in Respiratory Disease*, **2010**, 4, 161-76	4.9	8
70	Specificity of a quantitative real-time polymerase chain reaction assay for the detection of invasive pneumococcal disease: identifying streptococcus pneumoniae using quantitative polymerase chain reaction. *Chest*, **2010**, 137, 243-4	5.3	8
69	Genetic risk of acute pulmonary infections and sepsis. *Expert Review of Respiratory Medicine*, **2010**, 4, 229-38	3.8	8
68	Immunological markers of lung disease due to non-tuberculous mycobacteria. *Disease Markers*, **2010**, 29, 103-9	3.2	8

67	Corticosteroids for Community-Acquired Pneumonia: Overstated Benefits and Understated Risks. *Chest*, **2019**, 156, 1049-1053	5.3	7
66	Antibiotic Prescribing for Adults Hospitalized in the Etiology of Pneumonia in the Community Study. *Open Forum Infectious Diseases*, **2017**, 4, ofx088	1	7
65	Diagnosis of pleural infection: state-of-the-art. *Current Respiratory Care Reports*, **2012**, 1, 101-110		7
64	Clinical and epidemiological profile of patients with severe H1N1/09 pandemic influenza in Australia and New Zealand: an observational cohort study. *BMJ Open*, **2011**, 1, e000100	3	7
63	Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN). *Communicable Diseases Intelligence (2018)*, **2019**, 43,	1.9	7
62	Invasive Pneumococcal and Meningococcal Disease. *Infectious Disease Clinics of North America*, **2019** , 33, 1125-1141	6.5	7
61	Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2013: the Influenza Complications Alert Network. *Communicable Diseases Intelligence*, **2014**, 38, E143-9		7
60	Is Pulmonary non-Tuberculous Mycobacterial Disease Linked with a High Burden of Latent Cytomegalovirus?. *Journal of Clinical Immunology*, **2016**, 36, 113-6	5.7	6
59	Controlling epidemic viral infection. *Current Opinion in Infectious Diseases*, **2011**, 24, 130-6	5.4	6
58	Community-acquired pneumonia: genomics, epigenomics, transcriptomics, proteomics, and metabolomics. *Seminars in Respiratory and Critical Care Medicine*, **2012**, 33, 257-65	3.9	6
57	Pneumonia complicating the acute respiratory distress syndrome. *Seminars in Respiratory and Critical Care Medicine*, **2002**, 23, 443-8	3.9	6
56	Bacterial infection elicits heat shock protein 72 release from pleural mesothelial cells. *PLoS ONE*, **2013**, 8, e63873	3.7	6
55	Exercise training for adults hospitalized with an acute respiratory condition: a systematic scoping review. *Clinical Rehabilitation*, **2020**, 34, 45-55	3.3	6
54	High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis. *European Respiratory Journal*, **2017**, 50,	13.6	5
53	Monocyte-derived macrophages do not explain susceptibility to pulmonary non-tuberculous mycobacterial disease. *Clinical and Translational Immunology*, **2012**, 1, e2	6.8	5
52	Update on Stenotrophomonas maltophilia Infection in the ICU. *Clinical Pulmonary Medicine*, **2007**, 14, 17-22	0.3	5
51	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. *Anaesthesia, Critical Care & Pain Medicine*, **2020**, 39, 723-730	3	5
50	Empirical Therapy of Community-Acquired Pneumonia: Advancing Evidence or Just More Doubt?. *JAMA - Journal of the American Medical Association*, **2015**, 314, 396-7	27.4	4

49	Streptococcus pneumoniae potently induces cell death in mesothelial cells. *PLoS ONE*, **2018**, 13, e0201530	3.7	4
48	Antibiotic treatment outcomes in community-acquired pneumonia. *Turkish Journal of Medical Sciences*, **2018**, 48, 730-736	2.7	4
47	Lack of association of the caspase-12 long allele with community-acquired pneumonia in people of African descent. *PLoS ONE*, **2014**, 9, e89194	3.7	4
46	Severe community-acquired pneumonia: the need to customize empiric therapy. *Chest*, **2001**, 120, 1053-5	5.3	4
45	Systemic corticosteroids and community-acquired pneumonia-cautious optimism or wishful thinking?. *Journal of Thoracic Disease*, **2015**, 7, E622-4	2.6	4
44	Control Measures for Human Respiratory Viral Infection. *Seminars in Respiratory and Critical Care Medicine*, **2016**, 37, 631-9	3.9	4
43	Reduced Step Count and Clinical Frailty in Hospitalized Adults With Community-Acquired Pneumonia. *Respiratory Care*, **2020**, 65, 455-463	2.1	4
42	Advances in anti-fungal therapies. *Mycopathologia*, **2021**, 186, 665-672	2.9	4
41	Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2016: the Influenza Complications Alert Network (FluCAN). *Communicable Diseases Intelligence*, **2017**, 41, E337-E347		4
40	Beyond antibiotics for pulmonary nontuberculous mycobacterial disease. *Current Opinion in Pulmonary Medicine*, **2020**, 26, 260-266	3	3
39	Prevalence of oropharyngeal antibiotic-resistant flora among residents of aged care facilities: a pilot study. *Respirology*, **2015**, 20, 1139-41	3.6	3
38	Update in pulmonary infections 2010. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 186-90	10.2	3
37	The diagnostic dilemma in suspected ventilator-associated pneumonia: one size will never fit all. *Chest*, **2003**, 123, 335-7	5.3	3
36	Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN). *Communicable Diseases Intelligence (2018)*, **2019**, 43,	1.9	3
35	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. *Annals of the American Thoracic Society*, **2021**, 18, 1087-1097	4.7	3
34	Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2015: the Influenza Complications Alert Network. *Communicable Diseases Intelligence*, **2016**, 40, E521-E526		3
33	Pleural empyema caused by Klebsiella oxytoca: a case series. *Respirology*, **2015**, 20, 507-9	3.6	2
32	Advances in community-acquired pneumonia. *Therapeutic Advances in Infectious Disease*, **2020**, 7, 2049936120969607	3.8	2

31	Corticosteroids in Lung and Pleural Infections. *Current Pulmonology Reports*, **2018**, 7, 19-27	0.5	2
30	GM-CSF and influenza: will saving mice help humans?. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 157-8	10.2	2
29	Do we really want to know why only some smokers get COPD?. *Chest*, **2004**, 125, 1599-600	5.3	2
28	Are Blood Cultures Necessary in Community-Acquired Pneumonia?. *Clinical Pulmonary Medicine*, **2005**, 12, 146-152	0.3	2
27	Serological response to influenza vaccination among adults hospitalized with community-acquired pneumonia. *Influenza and Other Respiratory Viruses*, **2019**, 13, 208-212	5.6	2
26	Health Care-Associated Pneumonia: Is It Still a Useful Concept?. *Clinics in Chest Medicine*, **2018**, 39, 765-773	3.3	2
25	Antibiotic-resistant bacteria: COVID-19 hasn't made the challenge go away. *Respirology*, **2021**, 26, 1024-1026	3.6	2
24	Influenza epidemiology in adults admitted to sentinel Australian hospitals in 2014: the Influenza Complications Alert Network (FluCAN). *Communicable Diseases Intelligence*, **2015**, 39, E355-60		2
23	Reply to Skowronski and Chambers. *Clinical Infectious Diseases*, **2017**, 65, 355	11.6	1
22	Response. *Chest*, **2018**, 153, 763-764	5.3	1
21	Pulmonary tuberculosis: An analysis of isolation practices and clinical risk factors in a tertiary hospital. *Indian Journal of Tuberculosis*, **2019**, 66, 437-442	1.6	1
20	Pathogenic bacteria and TNF do not induce production of macrophage migration inhibitory factor (MIF) by human monocytes. *Cytokine*, **2009**, 46, 316-8	4	1
19	Genetic Effects on Sepsis and Pneumonia. *Clinical Pulmonary Medicine*, **2004**, 11, 143-153	0.3	1
18	Summary for Clinicians: Clinical Practice Guideline for the Diagnosis and Treatment of Community-acquired Pneumonia. *Annals of the American Thoracic Society*, **2020**, 17, 133-138	4.7	1
17	Scores to Predict Long-term Mortality in Patients With Severe Pneumonia Still Lacking. *Clinical Infectious Diseases*, **2021**, 72, e442-e443	11.6	1
16	Applying the lessons learned from coronavirus disease 2019 to improve pneumonia management. *Current Opinion in Infectious Diseases*, **2021**, 34, 175-179	5.4	1
15	Persistent Lung Inflammation After Clinical Resolution of Community-Acquired Pneumonia as Measured by FDG-PET/CT Imaging. *Chest*, **2021**, 160, 446-453	5.3	1
14	Limiting antibiotic use in lower respiratory tract infections: have we gone too far?. *Chest*, **2009**, 135, 1118-1120	5.3	

13	Community-acquired Pneumonia Guideline Recommendations-Impact of a Consensus-based Process versus Systematic Reviews. *Clinical Infectious Diseases*, **2021**, 73, e1467-e1475	11.6	0
12	Maladaptive Suppression of Bacterial Clearance in Early Sepsis. Setting the Scene for Failure. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 846-847	10.2	
11	Reply to Chahine, to Schuetz, and to Fabre. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 746-747	10.2	
10	Reply to Huttner : 2019 Community-acquired Pneumonia Treatment Guidelines: There Is a Need for a Change toward More Parsimonious Antibiotic Use. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 1316-1317	10.2	
9	Reply to Chalmers et al. *Clinical Infectious Diseases*, **2016**, 63, 1146-7	11.6	
8	371. *Critical Care Medicine*, **2014**, 42, A1449-A1450	1.4	
7	The Potential for Assessing the Bacterial Load of Streptococcus pneumoniae in Blood in Patients With Community-acquired Pneumonia. *Clinical Pulmonary Medicine*, **2011**, 18, 109-112	0.3	
6	Role of heat-shock protein 70 in multiple-organ dysfunction syndrome. *Journal of Organ Dysfunction*, **2006**, 2, 101-115		
5	Optimal Treatment of Severe Community-Acquired Pneumonia. *Current Respiratory Medicine Reviews*, **2007**, 3, 233-239	0.3	
4	What is pneumonia?. *Breathe*, **2021**, 17, 210087	1.8	
3	Pulmonary infections. *Current Opinion in Critical Care*, **1999**, 5, 67	3.5	
2	Clinical Practice Guidelines Versus Actual Clinical Practice: The Pneumonia Paradigm. *Clinical Infectious Diseases*, **2021**, 73, e1611-e1612	11.6	
1	Approach to Patients with Recurrent Ventilator-Associated Pneumonia257-272		